Format

Send to

Choose Destination
Am J Kidney Dis. 2015 Jul;66(1):133-46. doi: 10.1053/j.ajkd.2015.01.034. Epub 2015 May 7.

Calciphylaxis: risk factors, diagnosis, and treatment.

Author information

1
Division of Nephrology, Massachusetts General Hospital, Boston, MA. Electronic address: snigwekar@mgh.harvard.edu.
2
Department of Dermatology, Massachusetts General Hospital, Boston, MA.
3
Pathology Service, Dermatopathology Unit, Massachusetts General Hospital, Boston, MA.
4
Burn Service, Department of Surgery, Massachusetts General Hospital, Boston, MA.
5
Division of Cardiology, Massachusetts General Hospital, Boston, MA.
6
Palliative Care Division, Massachusetts General Hospital, Boston, MA.
7
Division of Nephrology, Massachusetts General Hospital, Boston, MA.

Abstract

Calciphylaxis is a rare but devastating condition that has continued to challenge the medical community since its early descriptions in the scientific literature many decades ago. It is predominantly seen in patients with chronic kidney failure treated with dialysis (uremic calciphylaxis) but is also described in patients with earlier stages of chronic kidney disease and with normal kidney function. In this review, we discuss the available medical literature regarding risk factors, diagnosis, and treatment of both uremic and nonuremic calciphylaxis. High-quality evidence for the evaluation and management of calciphylaxis is lacking at this time due to its rare incidence and poorly understood pathogenesis and the relative paucity of collaborative research efforts. We hereby provide a summary of recommendations developed by a multidisciplinary team for patients with calciphylaxis.

KEYWORDS:

Calcific uremic arteriolopathy; calciphylaxis; review; risk factors; sodium thiosulfate; warfarin

PMID:
25960299
PMCID:
PMC4696752
DOI:
10.1053/j.ajkd.2015.01.034
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center